Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.

NCT ID: NCT06157177

Last Updated: 2025-08-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-15

Study Completion Date

2025-11-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if a modification to metaxalone 640 mg can reduce low back and leg pain. The participants will be 18 to 80 years old, healthy with newly occurring back or leg pain. The main question aims to compare a group taking active treatment and a group taking a look-alike substance containing no active treatment. All participants will answer questions on Day 1, before treatment, and on 7-day after treatment, about:

* Amount and quality of pain
* Interference with physical activity
* Interference with sleep

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Double-blind, randomized, placebo-controlled, multi-center study of metaxalone 640 mg plus standard of care for patients with acute lumbo sacral musculoskeletal conditions with spinal stenosis and sciatica. Participants will be randomized 1:1. Following the initial pilot-study a second study will randomize a larger population of patients with appropriate power.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sciatica Acute Lumbar Spinal Stenosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active M640

Metaxalone micronized 640 mg over encapsulated tablet Taken orally every 6 hours for 7 days

Group Type ACTIVE_COMPARATOR

Metaxalone 640 mg Oral Tablet

Intervention Type DRUG

Metaxalone 640 mg used for the treatment of discomforts associated with acute, musculoskeletal pain.

Placebo

Inactive placebo capsule 640 mg Taken orally every 6 hours for 7 days

Group Type PLACEBO_COMPARATOR

Metaxalone 640 mg Oral Tablet

Intervention Type DRUG

Metaxalone 640 mg used for the treatment of discomforts associated with acute, musculoskeletal pain.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metaxalone 640 mg Oral Tablet

Metaxalone 640 mg used for the treatment of discomforts associated with acute, musculoskeletal pain.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Skelaxin un-micronized M640 metaxalone micronized

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* No clinically significant conditions impacting quality or quantity of pain
* Baseline Numeric Pain Scale ≥ 6
* Capable of answering text or email survey reminders
* Low back pain with or without sciatica

Exclusion Criteria

* Current use of other skeletal relaxants
* Current use of other pain relievers
* Current use of cimetidine or monoamine oxidase inhibitors
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Illumination Health

NETWORK

Sponsor Role collaborator

Primus Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

S Sodhi

Role: STUDY_DIRECTOR

Illumination Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

East Alabama Arthritis Center

Auburn, Alabama, United States

Site Status

Sean Wollaston, MD

Valley Village, California, United States

Site Status

Arthritis and Osteoporosis Center

Aventura, Florida, United States

Site Status

William Sunshine, MD

Boca Raton, Florida, United States

Site Status

Robert Levin, MD

Clearwater, Florida, United States

Site Status

5. CZ Rheumatology

Coral Springs, Florida, United States

Site Status

4. Palm Beach Rheumatology and Wellness

Jupiter, Florida, United States

Site Status

Family Arthritis Center

Loxahatchee Groves, Florida, United States

Site Status

Arthritis and Rheumatology Center of South Florida

Margate, Florida, United States

Site Status

Arthritis and Rheumatic Care Center

South Miami, Florida, United States

Site Status

Arthritis Research and Treatment Center

Stockbridge, Georgia, United States

Site Status

Jayashree Sinha, MD 1

Clovis, New Mexico, United States

Site Status

Carolina Rheumatology

Fayetteville, North Carolina, United States

Site Status

Ohio Arthritis and Osteoporosis Center of Southwest Ohio

Springboro, Ohio, United States

Site Status

Heritage Rheumatology & Arthritis Care

Colleyville, Texas, United States

Site Status

Integrative Rheumatology of South Texas

Harlingen, Texas, United States

Site Status

Southwest Research Group

Mesquite, Texas, United States

Site Status

DFW Rheumatology

Red Oak, Texas, United States

Site Status

Northern Virginia Center for Arthritis

Annandale, Virginia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PMMSS-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

BMS-741672 for Diabetic Neuropathic Pain
NCT00683423 COMPLETED PHASE2